A fixed-dose combination (FDC) of a sympathomimetic decongestant (Phenylephrine) and a first-generation alkylamine antihistamine (Triprolidine). It is primarily indicated for the symptomatic relief of allergic rhinitis and the common cold by reducing nasal congestion, sneezing, rhinorrhea, and itchy/watery eyes. Phenylephrine acts as a selective α1-adrenergic agonist, causing vasoconstriction in the nasal mucosa. Triprolidine is a potent H1-receptor antagonist with anticholinergic and sedative properties. This combination is widely used in the Indian OTC market for upper respiratory allergies and colds.
Adult: One tablet every 6 to 8 hours. The maximum recommended frequency is 4 times in 24 hours. Should not be used for more than 7 days for self-medication of cold symptoms.
Note: Administer orally with or without food. Taking with food may reduce potential GI upset. Tablet should be swallowed whole with a full glass of water. Do not crush or chew. Avoid taking dose late in the evening if sedation is undesirable during daytime.
The combination provides symptomatic relief through two distinct mechanisms. Phenylephrine acts as a direct sympathomimetic agonist on post-synaptic α1-adrenergic receptors in the vascular smooth muscle of the nasal mucosa. This causes vasoconstriction, reducing blood flow, edema, and nasal congestion. Triprolidine competitively and reversibly inhibits histamine at the H1 receptor sites, blocking the effects of endogenous histamine released during allergic reactions. It also possesses significant anticholinergic (antimuscarinic) activity, contributing to the drying of secretions.
Pregnancy: Pregnancy Category C (US FDA). Animal reproduction studies are not available. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Phenylephrine may reduce placental blood flow. Triprolidine has been associated with rare teratogenic effects in some studies. Avoid in first trimester unless absolutely necessary.
Driving: NOT ADVISABLE. Triprolidine causes significant drowsiness and impairs cognitive and motor functions. Patients should not drive or operate heavy machinery until their individual response is known (usually 24-48 hours after initiation).
| Monoamine Oxidase Inhibitors (MAOIs) - e.g., Phenelzine, Tranylcypromine | Marked potentiation of pressor effects of Phenylephrine, leading to severe hypertensive crisis, hyperpyrexia. | Contraindicated / Major |
| Beta-blockers (non-selective) - e.g., Propranolol | Unopposed alpha-adrenergic stimulation leading to severe hypertension and bradycardia. | Contraindicated / Major |
| Other Sympathomimetics (e.g., Pseudoephedrine, in cough syrups) | Additive pressor and CNS stimulant effects, increasing risk of hypertension and tachycardia. | Major |
| Antihypertensives (e.g., Methyldopa, Clonidine, Diuretics) | Phenylephrine may antagonize the hypotensive effect. | Moderate |
| Central Nervous System Depressants (e.g., Alcohol, Benzodiazepines, Opioids) | Additive sedative effect with Triprolidine, impairing mental and motor performance. | Major |
| Anticholinergic drugs (e.g., Atropine, TCAs, Antipsychotics) | Additive anticholinergic side effects (dry mouth, urinary retention, constipation, blurred vision). | Moderate |
| Digoxin | Triprolidine may mask the signs of digoxin toxicity (nausea, vomiting). | Moderate |